Mesenchymal Stem Cells - Advances And Applications

 Published On: Jul, 2015 |    No of Pages: 171 |  Published By: BioInformant | Format: PDF
Request Free Sample

This global strategic report is produced for:
• Management of stem cell companies
• Management of regenerative therapy companies
• Stem cell industry investors

It is designed to increase your efficiency and effectiveness in:
1. Commercializing mesenchymal stem cell (MSC) products, technologies, and therapies
2. Making intelligent investment decisions
3. Launching high-demand products
4. Selling effectively to your client base
5. Increasing revenue from MSC products and services
6. Taking market share from your competition

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

MSCs are advantageous over other stem cells types for a variety of reasons: they avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. Recently, there have been advances in the use of autologous mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, bone fractures, and more.

This global strategic report explores recent advances in MSC research applications, research priorities by market segment, and the competitive environment for MSC research products. It also identifies trend and growth patterns within the MSC industry. Because it is important for pharmaceutical companies interested to understand underlying forces affecting the MSC market, this report also presents a range of topics that apply to these companies, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

Literature and data concerning the biology and differentiation potential of mesenchymal stem cells (MSCs) has expanded rapidly over the past 10 years, with more than 13,000 publications now exploring aspects of MSC biology, behavior, and applications. In particular, MSCs appear to be an exceptionally promising tool for cell therapy because of their unusual characteristics, which partially mimic those of embryonic stem cells, while having advantages in terms of availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as from their ability to migrate to sites of tissue injury/inflammation or tumor growth. These localization properties present a promising strategy for targeted introduction of therapeutic agents through MSC gene therapy. In addition, MSCs possess strong immunosuppressive properties that medical researchers are exploiting for both autologous as well as heterologous therapies.

Clinical Progress with MSCs
As mentioned, mesenchymal stem cells (MSCs) have inspired a lot of activity over the past ten years as a novel therapeutic model for a wide range of diseases. Presently, MSCs-based clinical trials are being conducted for twelve types of disease conditions, with many completed trials showing their safety and efficacy.
The clinical utility of MSCs are mostly attributed to their four key biological properties, which are their potential to:
1. Migrate to sites of inflammation caused by tissue injury when injected intravenously
2. To get differentiated into different cell types
3. To release different bioactive molecules having the potential of stimulating recovery of injured cells and preventing inflammation
4. To accomplish immunomodulatory functions

Currently, there are 128 clinical trials involving MSCs are in progress in different parts of the world, including China, the European Union, the United States, the Middle East, and South Korea. Among these trials, 45 (35%) are exploiting MSCs for various disease indications. Currently, four major clinical trials using MSCs have reached Phase III. Stempeutics Research’s product candidate Stempeucel is being evaluated in two centers for treating critical leg ischemia. Prochymal is the product candidate from Osiris Therapeutics and it is being used for treating graft vs. host disease (GvHD). The company is also testing Prochymal for treating Crohn’s disease in another Phase III trial. The Australian company Mesoblast is testing an ‘off-the-shelf’ mesenchymal precursor product candidate for treating patients with hematological malignancies.

Since 1968, bone marrow transplantation (BMT) has been the gold standard treatment for blood cancer patients and others with genetic blood disorders. Each year more than 60,000 bone marrow transplantations are performed worldwide, and 58% of these procedures use autologous bone marrow and 42% of the cases use allogeneic bone marrow. Currently, the use of bone marrow is being replaced by the utilization of MSCs for some conditions.
The majority of cell therapy products currently being marketed are meant to address musculoskeletal conditions, and most of these products use MSCs as a component.

Report Objectives
The purpose of this report is to describe the current status of mesenchymal stem cells (MSCs) research, the ongoing clinical trials involving MSCs, late stage MSCs clinical trials, and the possible uses of MSCs in cell therapy. As MSC cell therapy is an integrated component of other cell therapies and regenerative medicines (RM), the report also gives a brief overview of the RM industry and overall cell therapy (CT) industry.

Thus, the main objectives are to consider the following:
• Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular.
• Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells.
• Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types.
• The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their sustained search for MSCs-based cell therapy products.

Key questions answered in this global strategic report are:
• How many companies are currently supporting the RM industry?
• What is the current regional breakdown of RM industry?
• How many RM products have been approved?
• What are the types of diseases are currently being pursued by RM companies?
• What are the major financial events, partnerships and acquisitions in RM sector?
• How do the large pharma companies perceive the value and long-term prospects of RM and CT?
• What are the major anticipated RM clinical events in 2015-16?
• What are the major therapeutic opportunities for the big pharma in RM and CT?
• How many CT product candidates have reached the Phase III stage and what are they?
• What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
• What are the major commercially available cell therapy products?
• What is the total number of cell therapy clinical trials at the global level?
• What are the major cell types used in cell therapy clinical trials?
• What are the major indications addressed by cell therapy clinical trials?
• What are the major cell therapy clinical trials that have reached Phase III?
• How many cell therapy clinical trials failed in the past year and what are they?
• What are the contributions of MSCs to the cell therapy industry?
• What are the biological properties of MSCs?
• What do MSCs get differentiated into?
• What bioactive molecules do the MSCs secrete?
• What are the immunomodulatory functions of MSCs?
• What are the factors impacting the acquisition of MSCs?
• What are the various sources of MSCs?
• What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
• What are the major clinical trials focusing on diabetes using BMMSCs?
• What are the major clinical trials involving BMMSCs for cardiovascular diseases?
• What are the major clinical trials focusing on liver diseases by BMMSCs?
• What are the brain-related diseases addressed by clinical trials using BMMSCs?
• How many clinical trials are conducted for intestinal diseases using MSCs?
• What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
• Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
• What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
• What is the current number of clinical trials using MSCs?
• How many major clinical trials using MSCs have reached the Phase III?
• What are the MSCs-based cell therapy products available in the market?

1. REPORT OVERVIEW 10
1.1 Statement of the Report 10
1.2 EXECUTIVE SUMMARY 12
2. INTRODUCTION 14
2.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview 16
2.2 Global Breakdown of Major RM Industries by Region 17
2.3 Breakdown of Global RM Companies by Type 18
2.4 Number of Therapeutic Companies, Approved Products and Clinical Trials in RM Sector 18
2.5 Number of RM Clinical Trials by Phase of Development 19
2.6 Number of RM Companies by Disease Focus Area 20
2.7 Major Financial Events in RM Industry 21
2.8 Major Partnerships and Acquisitions in RM Industry 21
2.9 Total Financings in RM Industry by Segment 22
2.10 Type of Financing for RM Industry 23
2.11 Major Regulatory Milestones in RM Industry 23
2.12 Major Data and Technology Events in RM Industry 24
2.13 Major Pharma and Biotech Companies Active in Advanced Therapies 25
2.14 Major Corporate Partnerships in RM Industry 26
2.15 Anticipated Major RM Clinical Events 28
2.16 Notable Deals and Acquisitions in RM, Cell and Gene Therapy Space, 2013-2014 29
2.17 Big Pharma’s Perception of RM 30
2.18.1 Major Therapeutic Opportunities for Big Pharma in Cell Therapy and RM 31
2.18.1.1 Current Opportunities 31
2.18.1.2 Near-Term Opportunities 31
2.18.1.3 Long-Term Opportunities 32
3. CELL THERAPY INDUSTRY: A BRIEF OVERVIEW 33
3.1 Types of Stem Cells Used in Cell Therapy 33
3.1.1 Human Embryonic Stem Cells (hESCs) 33
3.1.2 Induced Pluripotent Stem Cells (iPSCS) 33
3.1.3 Hematopoietic Stem Cells (HSCs) 34
3.1.4 Mesenchymal Stem Cells (MSCs) 34
3.1.5 Adipose Stem Cells (ASCs) 34
3.1.6 Neural Stem Cells (NSCs) 34
3.2 Cell Therapy Product Candidates in Late-Stage Clinical Development 35
3.3 Cell Therapy Product Candidates in Early-Stage Clinical Development 36
3.4 Cell Therapy Products Being Developed for Cardiovascular Indication 38
3.5 Cell Therapy Products Being Developed for Central Nervous System Indication 40
3.6 Cell Therapy Products Developed and Being Developed for Wound Care 41
3.7 Cell Therapy Products Developed and Being Developed for Spine and Orthopedics 42
3.8 Cell Therapy Products Being Developed for Diabetes 45
3.9 Cell Therapy Products Being Developed for Autoimmune Diseases 45
3.10 Combination of Cell and Gene Therapy Products in Development 46
3.11 Cancer Programs Utilizing the Combination of Cell and Immunotherapy 47
3.12 Major Commercially Available Cell Therapy Products 49
3.13 Cell Therapy Products Approved in South Korea 51
3.14 Cell Therapy Clinical Trials: An Overview 52
3.14.1 Cell Therapy Clinical Trials by Geography 52
3.14.2 Top Eight Countries in Cell Therapy Clinical Trials 53
3.14.3 Major Cell Types in Cell Therapy Clinical Trials 54
3.14.4 Major Disease Indications Addresses by Cell Therapy Clinical Trials 54
3.15 Fifteen Major Cell Therapies in Phase III 55
3.15.1 Prochymal 55
3.15.2 Mesenchymal Precursor Cell (MPC) 56
3.15.3 MyoCell 56
3.15.4 Ixmyelocel-T 56
3.15.5 ELAD 57
3.15.6 HP802 57
3.15.7 StemEx (Carlecortemcel-L) 57
3.15.8 LaViv 57
3.15.9 GSK 2696273 58
3.15.10 Renew 58
3.15.11 NT-501 (Renexus) 58
3.15.12 Neocart 58
3.15.13 DeNovo ET 59
3.15.14 MACI 59
3.16 Clinical Trial Failures in Cell Therapy in 2014 59
3.16.1 Failure of Phase II for MultiStem 59
3.16.2 Failure of Cardio 133 Trial 59
3.16.3 Termination of AlloCure’s ACT-AKI Trial 60
3.16.4 Failed Stroke Trial in India 60
3.16.5 Failure of HeartiCellGram-AMI Trial 60
3.16.6 Failure of Adipose MSCs in ARDS 60
3.16.7 CD133+ in CLI Not Feasible 60
3.16.8 Failed MSC Trial for Multiple Sclerosis 60
3.16.9 Failure of Chinese Diabetes Trial 61
3.16.10 Failed Efficacy Trial in AMI by Stempeucel 61
3.17 A Sampling of Stem and Progenitor Cell-Based Trials with 2014 Clinical Readouts 61
3.18 Major Cell Therapy Companies and their Locations 62
3.19 Involvement of Multinational Companies (MNCs) in Cell Therapy Sector 67
4. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW 69
4.1 Biological Properties of MSCs Contributing to their Therapeutic Effects 69
4.1.1 MSCs’ Capacity to Migrate and Engraft 69
4.1.2 MSCs’ Differentiation Potential 70
4.1.3 MSCs’ Potential to Secrete Multiple Bioactive Molecules 70
4.1.4 MSCs’ Potential for Immunomodulatory Functions 71
4.1.5 Variable Immunophenotype of MSCs 72
4.2 Factors Impacting MSCs Acquisition 73
4.3 Major Clinical Sources of MSCs 74
4.3.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs) 74
4.3.1.1 BMMSCs and Kidney 75
4.3.1.2 BMMSCs and Pancreas 75
4.3.1.3 BMMSCs and Heart 76
4.3.1.4 BMMSCs and Liver 76
4.3.1.5 BMMSCs and Brain 77
4.3.1.6 BMMSCs and Intestine 77
4.3.1.7 BMMSCs and Bone 78
4.3.2 Adipose-Derived Mesenchymal Stem Cells 79
4.3.2.1 Selected ADSC Secretomes and their Functions 80
4.3.3 Mesenchymal Stem Cells (MSCs) Derived from Wharton’s Jelly 81
4.3.3.1 Clinical Application Properties of WJ-MSCs 81
4.3.3.2 Immunoprivileged Status of WJ-MSCs 81
4.3.3.3 Clinical Applications of WJ-MSCs 81
4.3.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs) 83
4.4 Dominance of MSCs in Cell Therapy Clinical Trials 84
4.5 Major Diseases Addressed by MSCs in Current Clinical Trials 86
4.5.1 MSCs for Treating Liver Diseases 87
4.5.2 MSCs for Neurodegenerative Diseases 88
4.5.3 Clinical Trials Using MSCs for Autoimmune Diseases 88
4.5.4 Clinical Trials Using MSCs for Diabetes 89
4.5.5 MSCs for Cardiovascular Repair 90
4.5.6 MSCs for Musculoskeletal Diseases 90
4.5.6.1 Studies Using MSCs for Musculoskeletal Indications by Leading Countries 92
4.5.5.2 Application of MSCs in Joint Diseases 93
4.5.7 MSCs in Neuron/Spinal Cord Diseases 95
4.5.8 MSC Infusion for GvHD 96
4.5.9 MSCs for Crohn’s Disease 97
4.5.10 MSCs in Wound Healing 97
4.5.11 Increasing Focus on Immunological Properties of MSCs 99
4.5.12 Percentage of MSCs Clinical Trials by Different Phases 100
4.5.13 Selected MSCs Late-Stage Pipeline Cell Therapies 100
5. A BRIEF OVERVIEW OF THE MARKET FOR STEM CELLS 102
5.1 Global Market for Stem Cells by Disease Indication 105
6. SELECTED COMPANY PROFILES 107
6.1 American Type Culture Collection Inc. (ATCC) 107
6.2 Anterogen Co., Ltd. 108
6.2.1 Cupistem Injection 108
6.2.2 Queencell 108
6.3 Apceth GmbH & Co. KG 109
6.3.1 Apceth’s Research Areas 109
6.4 BioCardia Inc. 110
6.5 BioRestorative Therapies Inc. 111
6.5.1 brtxDISC 111
6.5.2 ThermoStem 111
6.6 Bone Therapeutics SA 112
6.6.1 PREOB 112
6.6.2 ALLOB 112
6.7 BrainStorm Cell Therapeutics Inc. 113
6.7.1 NurOwn 113
6.8 CellGenix Technologie Transfer GmbH 114
6.9 Celprogen Inc. 115
6.10 CellTherapies P/L 116
6.10.1 Services 116
6.10.2 Product 117
6.11 Cesca Therapeutics Inc. 117
6.11.1 Surgwerks 118
6.11.2 Cellwerks 118
6.11.3 AutoXress (AXP) 118
6.11.4 MarrowXpress (MXP) 118
6.11.5 Res-Q BMC 118
6.12 Cyagen Biosciences Inc. 119
6.12.1 Mesenchymal Stem Cells from Cyagen 119
6.12.2 Adipose-Derived Mesenchymal Stem Cells from Cyagen 120
6.12.3 Mesenchymal Stem Cells with GFP from Cyagen 120
6.12.4 Adipose-Derived Mesenchymal Cells with GFP from Cyagen 121
6.12.5 Stem Cell Culture Media from Cyagen 121
6.12.6 Stem Cell Differentiation Media from Cynagen 122
6.12.7 Primary Cells from Cynagen 122
6.12.8 Cyagen’s Cryopreservation Media 123
6.12.9 Cyagen’s Primary Cell Culture Media 124
6.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen 124
6.13 Cynata Therapeutics Ltd. 125
6.13.1 Cymerus Platform Technology 125
6.14 Cytori Therapeutics Inc. 126
6.14.1 Clinical Trial for Scleroderma 126
6.14.2 Clinical Trials for Osteoarthritis 126
6.15 Escape Therapeutics 127
6.16 Genlantis 128
6.17 Kite Pharma Inc. 129
6.17.1 Engineered Autologous Cell Therapy (eACT) 129
6.17.2 DC-Ad GM-CAIX 129
6.18 Life Technologies Corporation 130
6.19 Lonza Group Ltd. 131
6.19.1 Selected Products 131
6.20 Medipost Co. Ltd. 132
6.20.1 Cartistem 133
6.20.2 Neurostem 133
6.20.3 Pneumostem 133
6.21 Mesoblast Ltd. 134
6.21.1 Mesoblast’s Product Pipeline Overview 134
6.22 NuVasive Inc. 136
6.22.1 Osteocel 136
6.23 Octa Therapeutics Inc. 136
6.24 Organogenesis Inc. 137
6.24.1 Apligraf 137
6.24.2 Dermagraft 138
6.25 Orthofix International N.V. 138
6.25.1 Trinity Elite 138
6.25.2 Trinity Evolution 139
6.26 Osiris Therapeutics Inc. 139
6.26.1 Grafix 139
6.26.2 OvationOS 139
6.26.3 Cartiform 140
6.27 Pluristem Therapeutics Inc. 140
6.27.1 PLX Cells 140
6.28 PromoCell 141
6.29 Regeneus Ltd. 142
6.29.1 Products 142
6.30 ScienCell Research Laboratories 143
6.31 Stemcell Technologies Inc. 146
6.32 Stemedica Cell Technologies Inc. 149
6.32.1 Stemedyne MSC 149
6.32.2 Stemedyne NSC 149
6.32.3 Stemedyne RPE 149
6.33 Stempeutics Research Pvt. Ltd. 150
6.33.1 Stempeucel 150
6.33.2 Stempeutron 150
6.33.3 Stempeucare 151
6.34 TiGenix N.V. 151
6.34.1 Cx601 152
6.34.2 Cx611 152
6.34.3 Cx621 152
6.35 Vericel Corporation 153

INDEX OF FIGURES

FIGURE 3.1: Number of Cell Therapy Clinical Trials, 2011-2014 52
FIGURE 3.2: Cell Therapy Clinical Trials (%) by Geography in 2014 53
FIGURE 3.3: Top Eight Countries in Cell Therapy Clinical Trials (%) in 2014 53
FIGURE 3.4: Major Cell Types in Cell Therapy Clinical Trials (Numbers) in 2014 54
FIGURE 3.5: Major Cell Therapy Clinical Trials (Numbers) by Indication in 2014 55
FIGURE 4.1: Schematic of Factors Impacting MSC Acquisition 73
FIGURE 4.2: Number of Clinical Trials Using MSCs, 2004-2014 86
FIGURE 4.3: Increasing Focus on the Immunological Properties of MSCs 99
FIGURE 4.4: Percentage of MSCs Clinical Trials by Different Phases 100
FIGURE 5.1: Global Market for Stem Cells, Stem Cell Services, Cord Blood Banking, Stem Cell Therapies and Bone Marrow Transplants, Through 2021 104
FIGURE 5.2: Global Market for Stem Cells by Disease Indication, Through 2021 106

INDEX OF TABLES

TABLE 2.1: Global Breakdown of Major RM Industries by Region .….17
TABLE 2.2: Global Breakdown of RM Companies by Type, 2014….. 18
TABLE 2.3: Number of Therapeutic Companies, Approved Products and Clinical Trials, 2014…..19
TABLE 2.4: Number of RM Clinical Trials by Phase in 2014….....19
TABLE 2.5: Number of RM Companies by Disease Focus Area….…20
TABLE:2.6: Major Financial Events in RM Industry in 2014.21
TABLE 2.7: Major Partnerships and Acquisitions in RM Industry in 2014..22
TABLE 2.8: Total Financings in RM Industry by Segment in 2014.….22
TABLE 2.9: Type of Financing for RM Industry in 2013 and 2014…..23
TABLE 2.10: Major Regulatory Milestones in RM Industry in 2014…24
TABLE 2.11: Major Data and Technology Events in RM Industry in 201425
TABLE 2.12: Major Pharma and Biotech Companies Active in Advanced Therapies in 2014…..26
TABLE 2.13: Major Corporate Partnerships in RM Industry in 2014..27
TABLE 2.14: Anticipated Major RM Clinical Events in 2015…...28
TABLE 2.15: Notable Deals and Acquisitions in RM, Cell and Gene Therapy.29
TABLE 2.16: Big Pharma's Interest on Investing in RM by Sector….31
TABLE 2.17: Most Promising Areas in RM for Big Pharma.32
TABLE 3.1: Different Types of Stem Cells Used in Cell Therapy and their Characteristics...35
TABLE 3.2: Cell Therapy Product Candidates in Late-Stage Clinical Development36
TABLE 3.3: Cell Therapy Product Candidates in Early-Stage Clinical Development…..37
TABLE 3.4: Cell Therapy Products Being Developed for Cardiovascular Indication…...39
TABLE 3.5: Cell Therapy Products Being Developed for Central Nervous System.40
TABLE 3.6: Cell Therapy Products Developed and Being Developed for Wound Care..41
TABLE 3.7: Cell Therapy Products for Spine and Orthopedics...43
TABLE 3.8: Cell Therapy Products Being Developed for Diabetes…45
TABLE 3.9: Cell Therapy Products Being Developed for Autoimmune Diseases…46
TABLE 3.10: Combination of Cell and Gene Therapy Products in Development….47
TABLE 3.11: Cancer Programs Utilizing the Combination of Cell and Immunotherapy..48
TABLE 3.12: Major Commercially Available Cell Therapy Products..50
TABLE 3.13: Cell Therapy Products Approved in South Korea..51
TABLE 3.14: A Sampling of Stem and Progenitor Cell-Based Trials with 2014 Readouts….62
TABLE 3.15: Major Cell Therapy Companies in the World..63
TABLE 3.15: Major Cell Therapy Companies in the World (Continued)…64
TABLE 3.15: Major Cell Therapy Companies in the World (Continued)…65
TABLE 3.15: Major Cell Therapy Companies in the World (Continued)…66
TABLE 3.15: Major Cell Therapy Companies in the World (Continued)…67
TABLE 3.16: Major Companies and Products in Development in Cell Therapy Sector....67
TABLE 3.16: Major Companies and Products in Development in Cell Therapy (Continued…..…..68
TABLE 4.1: Origin and Cell Typed Derived from MSCs….....70
TABLE 4.2: Important Bioactive Molecules Secreted by MSCs and Their Functions…...71
TABLE 4.3: Immunomodulatory Effects of MSCs on Immune Cells....72
TABLE 4.4: Cell Surface Antigen Expressions of MSCs Isolaed from Different Sources..…..72
TABLE 4.5: Major Clinical Sources of MSCs...74
TABLE 4.6: A Sample of Clinical Trials Using BMMSCs for Kidney Diseases…...…75
TABLE 4.7: A Sample of Clinical Trials Using BMMSCs for Diabetes….....75
TABLE 4.8: A Sample of Clinical Trials Using BMMSCs for Heart Diseases…..…...76
TABLE 4.9: A Sample of Clinical Trials Using BMMSCs for Liver Diseases…..….…77
TABLE 4.10: Clinical and Experimental Therapies Using MSCs for Neural Diseases…..…....77
TABLE 4.11: A Sample of Clinical Trials Using MSCs for Intestinal Diseases...78
TABLE 4.12: A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases..…..78
TABLE 4.13: ADSCs Transplantation in Clinical Trials by Region in Phase III, 2014..….80
TABLE 4.14: Selected ADSC Secretomes and their Functions…..…..80
TABLE 4.15: A Summary of Clinical Trials Using WJ-MSCs.82
TABLE 4.15: A Summary of Clinical Trials Using WJ-MSCs (Continued)..83
TABLE 4.16: Clinical Trials Using UCBMSCs and Targeted Diseases..….84
TABLE 4.17: Dominance of MSCs in 2014 Stem Cells Clinical Trials.85
TABLE 4.18: Clinical Trials Using MSCs by Disease Type, 2014.…...87
TABLE 4.19: A Sample of Clinical Trials Using MSCs for Liver Diseases..87
TABLE 4.20: A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases….…88
TABLE 4.21: A Sample of Phase I and II Clinical Trials for Autoimmune Diseases….….89
TABLE 4.22: A Sample of Clinical Trials Using MSCs for Diabetes....89
TABLE 4.23: A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases..…..90
TABLE 4.24: Clinical Trials Involving MSCs for Bone and Cartilage Repair…...91
TABLE 4.25: Studies Using MSCs for Musculoskeletal Indications by Countries in 2014…...92
TABLE 4.26: A Sample of Current Clinical Trials Using MSCs for Osteoarthritis..…93
TABLE 4.27: A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair…..….….94
TABLE 4.28: Clinical Trials Using MSCs for Neuron and Spinal Cord Diseases...…95
TABLE 4.29: Clinical Experience of MSCs in GvHD Treatment…96
TABLE 4.30: A Sample of Clinical Trials Using MSCs for Crohn's Disease97
TABLE 4.31: Clinical Studies Using MSCs for Wound Healing…..…..98
TABLE 4.32: Selected MSCs Late-Stage Pipeline Therapies…...….101
TABLE 5.1: Global Market for Stem Cells, Through 2021….…..104
TABLE 5.2: Global Market for Stem Cells by Disease Indication, Through 2021.….…..106
TABLE 6.1: BioCardia's Product Pipeline Overview.…110
TABLE 6.2: Bone Therapeutics' Product Pipeline….….…...113
TABLE 6.3: Cyagen's Mesenchymal Cells…...….119
TABLE 6.4: Cyagen's Adipose-Derived MSCs…..120
TABLE 6.5: Cyagen's MSCs with GFP….…..120
TABLE 6.6: Cyagen's Adipose-Derived MSCs with GFP....121
TABLE 6.7: Cyagen's Stem Cell Culture Media....122
TABLE 6.8: Cyagen's Stem Cell Differentiation Media…....122
TABLE 6.9: Primary Cells from Cyagen..123
TABLE 6.10: Cyagen's Cryopreservation Media...123
TABLE 6.11: Cyagen's Primary Cell Culture Media..…124
TABLE 6.12: General Cell Culture Supplements and Specialty Reagents from Cyagen…..….....125
TABLE 6.13: Escape Therapeutics' Pipeline Products.…...127
TABLE 6.14: Kite Pharma's Pipeline and Clinical Trials…..130
TABLE 6.15: Mesoblast's Product Pipeline Overview….….135
TABLE 6.16: Octa's Pipeline of Therapeutic Programs…...135
TABLE 6.17: Regeneus' Product Pipeline..…143
TABLE 6.18: Stempeucel in Clinical Trials by Indication…..151
TABLE 6.19: Vericel Corporation's Product Portfolio.......…153
TABLE 6.20: Summary Table for the Companies and Their Product Types ...154


If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.